Latest filing published 07 May 2012 for HAEMONETICS CORP, €335k.
Insider track record
No signal scores available.
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +40.2%Entry US$28.70 · Close at T+365 US$40.22
- +6.2%Entry US$33.63 · Close at T+365 US$35.72
- -0.7%Entry US$29.39 · Close at T+365 US$29.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Mikael Gordon: trading record in brief
Mikael Gordon is a declared insider of Haemonetics Corp, with filings sourced from SEC (Form 4). Over a trading history stretching from 22 January 2008 to 3 May 2012, the count stands at 26 filings.
The open-market side counts 3 purchases for €23k alongside 11 sales for €2.7M. Netting one side against the other leaves €2.6M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 6 share grants and 6 option exercises. Since January 2012: no purchases and 9 sales on the market.
A typical purchase (the median) is worth €8,110. Ninety days after publication, 3 purchases show a median change of +2.4%, with the price up in 67% of them. They describe history only and say nothing certain about the share price ahead.
On 7 May 2012 came the latest disclosure, an option exercise for €335k in Haemonetics Corp. The last insider purchase was made public on 7 November 2011, 5,481 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Mikael Gordon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,000 shares@ US$55.14Common StockSEC:0000313143-12-000061:0
- 8,000 shares@ US$71.50Common StockSEC:0000313143-12-000061:1
- 4,000 shares@ US$55.14Common StockSEC:0000313143-12-000058:0
- 4,000 shares@ US$72.50Common StockSEC:0000313143-12-000058:1
- 228 shares@ US$71.88Common StockSEC:0000313143-12-000059:0
- 9,793 shares@ US$52.94Common StockSEC:0000313143-12-000059:1
- 9,793 shares@ US$71.87Common StockSEC:0000313143-12-000059:2
- 2,168 shares@ US$71.94Common StockSEC:0000313143-12-000059:3
- 4,735 shares@ US$54.99Common StockSEC:0000313143-12-000059:4
- 4,735 shares@ US$71.87Common StockSEC:0000313143-12-000059:5
- 11,435 shares@ US$54.55Common StockSEC:0000313143-12-000059:6
- 11,435 shares@ US$71.87Common StockSEC:0000313143-12-000059:7
- 6,980 shares@ US$55.14Common StockSEC:0000313143-12-000059:8
- 6,980 shares@ US$71.87Common StockSEC:0000313143-12-000059:9
- 890 shares@ US$70.00Common StockSEC:0000313143-12-000022:0
- 228 shares@ US$51.81Common StockSEC:0000313143-11-000129:0Canonical exit: 1 Feb 2012 (T+90)
- 1,955 shares@ US$0.01Common StockSEC:0000313143-11-000102:0
- 100 shares@ US$67.28Common StockSEC:0000313143-11-000039:0
- 357 shares@ US$67.27Common StockSEC:0000313143-11-000039:1
- 257 shares@ US$46.80Common StockSEC:0000313143-11-000030:0Canonical exit: 2 Aug 2011 (T+90)
- 200 shares@ US$46.34Common StockSEC:0000313143-10-000092:0Canonical exit: 2 Feb 2011 (T+90)
- 2,182 shares@ US$0.01Common StockSEC:0001209191-10-052234:0
- 952 shares@ US$0.01Common StockSEC:0000313143-09-000076:0
- 1,224 shares0Common StockSEC:0000313143-09-000077:0
- 1,186 shares@ US$0.01Common StockSEC:0000313143-08-000008:0
25 of 25 declarations
